SLSN SOLESENCE, INC.
FY2024 10-K
SOLESENCE, INC. (SLSN) filed its fiscal year 2024 10-K annual report with the SEC on Mar 31, 2025. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.
AI Filing AnalysisFY2024 10-K
Business Overview
- • Core business shifted to vertically integrated skin health consumer products leveraging proprietary Active Stress Defense™ nano-technology platform
- • New emphasis on expanding finished product manufacturing and formulation capabilities for clean, inclusive UV/environmental protection goods
Management Discussion & Analysis
- • Revenue $52.3M in 2024 vs $37.3M in 2023, up $15.0M or 40.4% YoY, driven by product revenue increase to $51.9M from $36.6M
- • Gross profit $16.2M vs $7.8M; gross margin 30.9% vs 21.0%; operating income $5.1M vs loss $3.5M; net income $4.2M vs loss $4.4M
Financial SummaryXBRL
Revenue
$52M
Net Income
$4M
Gross Margin
30.9%
Operating Margin
9.8%
Net Margin
8.1%
ROE
28.3%
Total Assets
$50M
EPS (Diluted)
$0.07
Operating Cash Flow
$2M
Source: XBRL data from SOLESENCE, INC. FY2024 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on SOLESENCE, INC.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.